Processa Pharmaceuticals

Processa Pharmaceuticals CROIC

The Cash Return on Invested Capital (CROIC) of Processa Pharmaceuticals (PCSA) as of Oct 16, 2026 is -204.13 %. In the previous year, Cash Return on Invested Capital (CROIC) was -635.61 % — a change of -67.88% (higher).

CROIC

-204.13 %

YoY

-67.88%

Last updated:

Cash Return on Invested Capital (CROIC) of Processa Pharmaceuticals is 2025 -204.13 % . Cash Return on Invested Capital (CROIC) of Processa Pharmaceuticals was 2024 -635.61 % . It decreases by -67.88% higher compared to the previous year.

The Processa Pharmaceuticals CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-37.54 USD
Jan 1, 2019
-30.42 USD
Jan 1, 2020
-13.51 USD
Jan 1, 2021
-34.10 USD
Jan 1, 2022
-124.74 USD
Jan 1, 2023
-156.94 USD
Jan 1, 2024
-635.61 USD
Jan 1, 2025
-204.13 USD
The Processa Pharmaceuticals CROIC history
YEARCROICYoY
-204.13 %-67.88%
-635.61 %+305.01%
-156.94 %+25.81%
-124.74 %+265.80%
-34.10 %+152.43%
-13.51 %-55.59%
-30.42 %-18.97%
-37.54 %-36.76%
-59.37 %-141.63%
142.60 %0.00%
142.60 %-212.70%
-126.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Processa Pharmaceuticals Stock analysis

What does Processa Pharmaceuticals do? Processa Pharmaceuticals Inc, listed under ticker PCSA with ISIN US74275C4033, is headquartered in Hanover, Maryland, United States. The company operates in the Health Care sector within the Pharmaceuticals industry. It has 12 employees. Processa Pharmaceuticals went public on October 7, 2013. The company focuses on developing drug products to address serious medical conditions with unmet needs, targeting treatments for Necrobiosis Lipoidica and head and neck cancer effects. Processa Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Processa Pharmaceuticals stock

Cash Return on Invested Capital (CROIC) of Processa Pharmaceuticals is -204.13 % in 2025.

Cash Return on Invested Capital (CROIC) of Processa Pharmaceuticals changed from -635.61 % to -204.13 %, representing a -67.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Processa Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Processa Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Processa Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Processa Pharmaceuticals